Prevail Therapeutics

OverviewSuggest Edit

Prevail Therapeutics is a biotech company that is developing therapeutics for neurodegenerative disorders, such as Parkinson's disease. It establishes a pipeline of programs that includes discovery-phase and preclinical development efforts.

TypePublic
Founded2017
HQNew York, US
Websiteprevailtherapeutics.com

Latest Updates

Employees (est.) (Sept 2019)48(+10%)
Job Openings2
Share Price (Nov 2020)$10.1
Cybersecurity ratingAMore

Key People/Management at Prevail Therapeutics

Asa Abeliovich

Asa Abeliovich

CEO & Founder, Director
Franz Hefti

Franz Hefti

Chief Development Officer
Yong Dai

Yong Dai

Chief Technology Officer
Jeffrey Sevigny

Jeffrey Sevigny

Chief Medical Officer
Brett Kaplan

Brett Kaplan

Chief Financial Officer
Emily Minkow

Emily Minkow

Chief Business Officer
Show more

Prevail Therapeutics Office Locations

Prevail Therapeutics has an office in New York
New York, US (HQ)
430 E 29th St #940
Show all (1)

Prevail Therapeutics Financials and Metrics

Prevail Therapeutics Revenue

USD

Net income (Q2, 2020)

(22.1m)

EBIT (Q2, 2020)

(22.2m)

Market capitalization (20-Nov-2020)

347.3m

Closing stock price (20-Nov-2020)

10.1

Cash (30-Jun-2020)

111.1m

EV

246.8m
Prevail Therapeutics's current market capitalization is $347.3 m.
Annual
USDFY, 2017FY, 2018FY, 2019

General and administrative expense

803.7k4.7m17.0m

R&D expense

995.4k14.1m48.8m

Operating expense total

1.8m18.8m65.8m

EBIT

(1.8m)(18.8m)(65.8m)
Quarterly
USDQ1, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

641.2k1.9m3.7m4.5m7.9m9.2m

R&D expense

1.3m8.4m12.0m16.8m11.4m12.9m

Operating expense total

1.9m10.3m15.7m21.3m19.3m22.2m

EBIT

(1.9m)(10.3m)(15.7m)(21.3m)(19.3m)(22.2m)
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

12.7m63.0m168.1m

Prepaid Expenses

104.7k562.7k6.4m

Current Assets

12.8m63.6m174.5m

PP&E

106.1k677.9k2.5m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

100.3m202.1m183.1m149.6m111.1m

Prepaid Expenses

4.4m4.3m7.4m4.9m4.6m

Current Assets

104.7m206.3m190.5m154.5m122.1m

PP&E

897.5k2.1m2.5m2.7m2.7m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(1.8m)(19.1m)(63.2m)

Depreciation and Amortization

2.0k54.9k265.0k

Accounts Payable

265.4k976.0k3.9m

Cash From Operating Activities

(987.3k)(14.0m)(55.8m)
Quarterly
USDQ1, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(3.2m)(9.9m)(25.0m)(45.3m)(18.6m)(40.7m)

Depreciation and Amortization

5.1k36.8k93.0k201.0k111.0k225.0k

Accounts Payable

459.7k713.2k762.0k3.7m(1.2m)(3.2m)

Cash From Operating Activities

(1.2m)(12.3m)(22.5m)(41.0m)(18.2m)(36.6m)
USDFY, 2017

Debt/Equity

1.7 x

Debt/Assets

0.3 x

Financial Leverage

5.5 x
Show all financial metrics

Prevail Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

Prevail Therapeutics Online and Social Media Presence

Embed Graph

Prevail Therapeutics News and Updates

Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the United States Patent and Trademark Office (USPTO) o…

Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

Patient Dosing Continues in the Phase 1/2 PROPEL Trial of PR001 for Parkinson’s Disease with GBA1 Mutations

Prevail Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights

Preliminary Data Demonstrates Normalization of CSF GBA1 Enzyme Activity in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher Disease Patients

Prevail Therapeutics Reports Full Year 2019 Financial Results and Business Highlights

Dosing Initiated in PROPEL Phase 1/2 Trial of PR001 for Treatment of Parkinson’s Disease with GBA1 Mutations

Prevail Therapeutics to Present at Upcoming Conferences

NEW YORK, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that management will present at…

Prevail Therapeutics Announces IND Active for PR001 for Treatment of Neuronopathic Gaucher Disease

NEW YORK, Dec. 26, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or the “Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the U.S. Food and Drug Adm…
Show more

Prevail Therapeutics Blogs

Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO

Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO Content Import Mon, 11/02/2020 - 07:02 Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO November 2, 2020 at 7:00 AM …

Prevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Prevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Liz.McPherson@… Fri, 09/18/2020 - 15:05 Prevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit September 18, 2020 at 3:04 PM EDT …

Prevail Therapeutics Announces Appointment of William H. Carson, M.D., to Board of Directors

NEW YORK , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc.  (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced the appointment of William H.

Prevail Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results

Prevail Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results Content Import Wed, 08/05/2020 - 16:03 Prevail Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results August 5, 2020 at 4:01 PM EDT This release …

Prevail Therapeutics to Highlight Multiple Gene Therapy Programs for Neurodegenerative Diseases at the Virtual 2020 Alzheimer’s Association International Conference

Prevail Therapeutics to Highlight Multiple Gene Therapy Programs for Neurodegenerative Diseases at the Virtual 2020 Alzheimer’s Association International Conference Content Import Wed, 07/22/2020 - 17:01 Prevail Therapeutics to Highlight Multiple Gene Therapy Programs for Neurodegenerative…

Prevail Therapeutics Appoints Kira Schwartz, J.D., as General Counsel

Prevail Therapeutics Appoints Kira Schwartz, J.D., as General Counsel Content Import Thu, 06/04/2020 - 07:01 Prevail Therapeutics Appoints Kira Schwartz, J.D., as General Counsel June 4, 2020 at 7:00 AM EDT This release is a backfill from a News Wire …
Show more

Prevail Therapeutics Frequently Asked Questions

  • When was Prevail Therapeutics founded?

    Prevail Therapeutics was founded in 2017.

  • Who are Prevail Therapeutics key executives?

    Prevail Therapeutics's key executives are Asa Abeliovich, Franz Hefti and Yong Dai.

  • How many employees does Prevail Therapeutics have?

    Prevail Therapeutics has 48 employees.

  • Who are Prevail Therapeutics competitors?

    Competitors of Prevail Therapeutics include Molecular Partners, NeuroVive Pharmaceutical and ViewPoint Therapeutics.

  • Where is Prevail Therapeutics headquarters?

    Prevail Therapeutics headquarters is located at 430 E 29th St #940, New York.

  • Where are Prevail Therapeutics offices?

    Prevail Therapeutics has an office in New York.

  • How many offices does Prevail Therapeutics have?

    Prevail Therapeutics has 1 office.